Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial.
Antiretroviral Therapy, Highly Active
Antirheumatic Agents
/ therapeutic use
Auranofin
/ therapeutic use
CD4 Lymphocyte Count
DNA, Viral
/ drug effects
HIV Fusion Inhibitors
/ therapeutic use
HIV Infections
/ drug therapy
HIV Integrase Inhibitors
/ therapeutic use
HIV-1
/ drug effects
Heterocyclic Compounds, 3-Ring
/ therapeutic use
Humans
Maraviroc
/ therapeutic use
Oxazines
Piperazines
Proviruses
/ drug effects
Pyridones
Virus Latency
/ drug effects
Antiproliferative agent
Disease-modifying antirheumatic agent
HIV cure
HIV reservoir
Proviral DNA
Viral evolution
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
23
04
2019
revised:
17
07
2019
accepted:
01
08
2019
pubmed:
9
8
2019
medline:
5
3
2020
entrez:
9
8
2019
Statut:
ppublish
Résumé
Antiretroviral therapy (ART) is typically composed of a combination of three antiretroviral drugs and is the treatment of choice for people with human immunodeficiency virus type 1/acquired immune deficiency syndrome (HIV-1/AIDS). However, it is unable to impact on viral reservoirs, which harbour latent HIV-1 genomes that are able to reignite the infection upon treatment suspension. The aim of this study was to provide an estimate of the safety of the disease-modifying antirheumatic agent auranofin and its impact on the HIV-1 reservoir in humans under intensified ART. For this purpose, an interim analysis was conducted of three of the six arms of the NCT02961829 clinical trial (five patients each) with: no intervention, i.e. continuation of first-line ART; intensified ART (ART + dolutegravir and maraviroc); and intensified ART plus auranofin. Auranofin treatment was found to be well tolerated. No major adverse events were detected apart from a transient decrease in CD4
Identifiants
pubmed: 31394172
pii: S0924-8579(19)30212-2
doi: 10.1016/j.ijantimicag.2019.08.001
pii:
doi:
Substances chimiques
Antirheumatic Agents
0
DNA, Viral
0
HIV Fusion Inhibitors
0
HIV Integrase Inhibitors
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
Auranofin
3H04W2810V
dolutegravir
DKO1W9H7M1
Maraviroc
MD6P741W8A
Banques de données
ClinicalTrials.gov
['NCT02961829']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
592-600Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.